Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.
|
[14-February-2024] |
TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the press release is issued are invited to contact the company at IR@chemomab.com. About Chemomab Therapeutics Ltd. Contacts: Media and Investors:
SOURCE Chemomab Therapeutics Ltd |
||
Company Codes: NASDAQ-NMS:CMMB |